Anderson M, Collison K, Drummond MB, et al. - This analysis of two clinical trials and a real-world population of chronic obstructive pulmonary disease (COPD) patients was sought to ascertain spirometric peak inspiratory flow (PIF) distribution and investigate the relationship between PIF and outcomes. Fluticasone furoate/umeclidinium/vilanterol via ELLIPTA DPI vs budesonide/formoterol+tiotropium in COPD patients were evaluated in this replicate phase 4, 12-week, randomized, double-blind trial. Researchers tested spirometric PIF distribution at screening and the association between PIF and lung function outcomes in the pooled 207,608/207,609 population. The study enrolled a sum of 1,460 (207,608/207,609) and 3,282 (KPNW) patients. Through the ELLIPTA DPI, nearly all COPD patients in the 207608/207609 and KPNW populations achieved spirometric PIF values calculated as equivalent to PIFR of ≥ 30 L/min. The results indicated that lack of association between spirometric PIF at screening and treatment efficacy aligns with consistent dose performance from the ELLIPTA DPI across a wide range of PIFs, achieved by patients with COPD of all severities.